Shots:

• The BTD is based on a P-Ib/II TRANQUILITY study assessing BXCL501 in patients with acute treatment of agitation associated with dementia- including AD
• The results demonstrated significant reductions in agitation measures @2hrs. post-dose with both 30 and 60 mcg doses as measured by multiple scales. The dose dependent response has the potential to support the company’s plans to evaluate BXCL501 for use across the full range of dementia care settings
• BXCL501 is an orally dissolving thin film formulation of dexmedetomidine which is a selective alpha-2a receptor agonist for agitation and opioid withdrawal symptoms

 ­ Ref: GlobeNewswire | Image: Linkedin